Fulcrum Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $282.18M
- P/E (TTM)
- –
- Dividend yield
- –
About Fulcrum Therapeutics
Pharmaceutical Preparations, SIC 2834
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies to treat genetically defined rare diseases. Its lead product candidate is pociredir, an investigational oral drug engineered to stimulate fetal hemoglobin production to address the biological causes of sickle cell disease. The company also investigates drug candidates for conditions such as prostate cancer and beta-thalassemia through cellular target discovery methods. Fulcrum Therapeutics operates as a single business focused on benign hematology and genetic conditions, targeting affected patients and the hematologists who provide their clinical care.
The company maintains its corporate headquarters in Cambridge, Massachusetts, where it leases office and laboratory space. Its clinical development efforts and operational activities take place primarily in the United States, alongside regulatory outreach planned for Europe. Fulcrum Therapeutics currently has one product candidate in clinical trials and relies on external contract manufacturing organizations to produce its drug supplies as well as third-party partners to manage its clinical studies.
Summary of the business section of Fulcrum Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Fulcrum Therapeutics, Inc.
- Founded
- 2016
- Headquarters
- Cambridge, MA
- Address
- 26 Landsdowne Street 02139
- Phone
- (617) 651-8851
- Website
- www.fulcrumtx.com
- Employees
- 55, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- FULC
- Exchange
- Nasdaq
- IPO date
- Jul 18, 2019
- Shares outstanding
- 76M, Jul 23, 2026
- Public float
- $296.08M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1680581
- CUSIP
- 359616109
- ISIN
- US3596161097
- EIN
- 47-4839948
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Alex Sapir | See Remarks, Director | 193,360 |
| Alan A. Musso | Chief Financial Officer | 0 |
| Greg Tourangeau | Principal Accounting Officer | 14,062 |
| Curtis Gale Oltmans | Chief Legal Officer | 10,252 |
| Alan Ezekowitz | Director | 10,927 |
| James A. Geraghty | Director | 90,714 |
| Katina Dorton | Director | 0 |
| Robert J. Gould | Director | 454,864 |
| Kate Haviland | Director | – |
| Colin Hill | Director | 0 |
| Sonja Banks | Director | 0 |
| Rachel K. King | Director | – |
| Joshua Lehrer-Graiwer | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Alex Sapir | $3.25M | $14.93M | $1.64M | $15536 | – |
| FY2025 Bryan Stuart | $0 | $0 | $1.64M | $15536 | – |
| FY2025 Robert JGould | $0 | $0 | $1.64M | $15536 | – |
| FY2024 Alex Sapir | $1.00M | -$3.26M | $2.14M | $6456 | – |
| FY2024 Bryan Stuart | $0 | $0 | $2.14M | $6456 | – |
| FY2024 Robert JGould | $0 | $0 | $2.14M | $6456 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of February 17, 2026, we had 55 full-time employees, including a total of 19 employees with M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 2, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jul 18, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 12, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |